- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Milan: Philogen in the red | 4 | Teleborsa | ||
| 25.06. | Milan: Philogen in turmoil | 2 | Teleborsa | ||
| 12.06. | Milan: Philogen falls | 2 | Teleborsa | ||
| 11.06. | Bristol Myers bolsters radiopharma portfolio with PhiloChem deal | 8 | BioPharma Dive | ||
| 11.06. | Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio | 1 | Contract Pharma | ||
| 11.06. | Bristol-Myers' RayzeBio signs a license deal with Philochem | 4 | Seeking Alpha | ||
| PHILOGEN Aktie jetzt für 0€ handeln | |||||
| 11.06. | BMS' radiopharma unit builds with $1.35bn Philochem deal | 8 | pharmaphorum | ||
| 11.06. | Philogen S.p.A.: Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.3 | 532 | GlobeNewswire (Europe) | Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales
OTELFINGEN... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 80,50 | 0,00 % | Goldman Sachs nimmt Nuvalent-Aktie mit Kaufempfehlung in die Bewertung auf | ||
| RECURSION PHARMACEUTICALS | 5,210 | 0,00 % | Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? | ||
| CG ONCOLOGY | 26,680 | +1,25 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,890 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Beam Therapeutics mit Kursziel von 80 US-Dollar | ||
| ENLIVEN THERAPEUTICS | 20,640 | +5,04 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| TREVI THERAPEUTICS | 5,980 | 0,00 % | Cantor Fitzgerald initiates coverage on Trevi Therapeutics stock with Overweight rating | ||
| PHATHOM PHARMACEUTICALS | 8,910 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 22,650 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,010 | +1,48 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| TANGO THERAPEUTICS | 5,650 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ... | BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
| IMMUNOME | 8,630 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| HARMONY BIOSCIENCES | 32,110 | 0,00 % | Pre-market Movers: Alti Global, CXApp, PAM Transportation Services, Harmony Biosciences, iCoreConnect | ROME (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 09.15 A.M. ET).In the Green CXApp Inc (CXAI) is up over 37% at $1.11.
PAM Transportation... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 2,920 | 0,00 % | Morgan Stanley initiates Sana Biotechnology stock with Overweight rating | ||
| RELAY THERAPEUTICS | 3,600 | +2,27 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 44,370 | +0,11 % | Guggenheim reiterates Buy on Apogee Therapeutics stock ahead of key data |
Das Unternehmen PHILOGEN SPA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 21,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHILOGEN SPA finden Sie auf Wallstreet Online.